Volume 7 Issue 1
Jun.  2023
Turn off MathJax
Article Contents
Article Navigation >  Blood&Genomics  > 2023  >  7(1): 55-60
Jia Liu, Peiyan Kong, Lidan Zhu, Shichun Gao, Huanfeng Liu, Lu Wang, Cheng Zhang, Li Gao, Xi Zhang, Lei Gao. Analysis of the clinical efficacy of penciclovir in the prevention of viral infection after allogeneic hematopoietic stem cell transplantation[J]. Blood&Genomics, 2023, 7(1): 55-60. doi: 10.46701/BG.2023012022025
Citation: Jia Liu, Peiyan Kong, Lidan Zhu, Shichun Gao, Huanfeng Liu, Lu Wang, Cheng Zhang, Li Gao, Xi Zhang, Lei Gao. Analysis of the clinical efficacy of penciclovir in the prevention of viral infection after allogeneic hematopoietic stem cell transplantation[J]. Blood&Genomics, 2023, 7(1): 55-60. doi: 10.46701/BG.2023012022025
shu

Analysis of the clinical efficacy of penciclovir in the prevention of viral infection after allogeneic hematopoietic stem cell transplantation

doi: 10.46701/BG.2023012022025

  • Medical Center of Hematology, Xinqiao Hospital; State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical University, Chongqing 400037, China

More Information
  • Corresponding author: Xi Zhang and Lei Gao, Medical Center Hematology, Xinqiao Hospital; State Key Laboratory of Trauma, Burns and Combined Injury, Army Medical University, 83 Xinqiaozheng Street, Shapingba District, Chongqing 400037, China. E-mails: zhangxxi@sina.com and gaolei7765@163.com
  • Received Date: 2022-10-07
  • Rev Recd Date: 2023-03-20
  • Accepted Date: 2023-03-27
    • Available Online: 2023-07-05
  • Publish Date: 2023-06-30
    Abstract
  • This study aims to retrospectively analyze the efficacy of penciclovir in the prevention of viral infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ninety-six patients with allo-HSCT were enrolled, who were treated at the Medical Center of Hematology of Xinqiao Hospital from June 2020 to September 2021. The experimental and control groups were treated with penciclovir and acyclovir, respectively, to prevent viral infection. By February 2022, the infection rates of cytomegalovirus, BK virus, JC virus, and Epstein-Barr virus (EBV) in the experimental group and the control group were 18.8% and 39.06% (P<0.05), 28.1% and 25% (P>0.05), 6.2% and 7.81% (P>0.05), 21.8% and 23.43% (P>0.05), respectively. The infection-related urinary system symptoms of the experimental group and the control group occurred in 4 and 9 patients, respectively, of which 3 and 9 patients died, respectively. Penciclovir can significantly reduce the cytomegalovirus infection rate after allo-HSCT and has better preventive effects than acyclovir without obvious side effects. The effectiveness and safety of penciclovir will be further verified in the future.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    Kaito S, Nakajima Y, Hara K, et al. Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation[J]. Blood Adv, 2020, 4(6): 1051−1061. doi: 10.1182/bloodadvances.2019000814
    [2]
    Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients[J]. Hematol Oncol Clin North Am, 2011, 25(1): 151−169. doi: 10.1016/j.idc.2010.01.008
    [3]
    Wang LL, Mo WJ, Zhang YP, et al. Clinical analysis of CMV infection after allogeneic hematopoietic stem cell transplantation in severe aplastic anemia[J]. J Exp Hematol, 2021, 29(3): 944−950. doi: 10.19746/j.cnki.issn.1009-2137.2021.03.046
    [4]
    Jakharia N, Howard D, Riedel DJ. CMV infection in hematopoietic stem cell transplantation: prevention and treatment strategies[J]. Curr Treat Options Infect Dis, 2021, 13(3): 123−140. doi: 10.1007/s40506-021-00253-w
    [5]
    Foolad F, Aitken SL, Chemaly RF. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients[J]. Expert Rev Clin Pharmacol, 2018, 11(10): 931−941. doi: 10.1080/17512433.2018.1500897
    [6]
    Guo D, Li HY, Qin C. Analysis of the efficacy of penciclovir in the prevention and treatment of cytomegalovirus pneumonia[J]. Chin Hosp Pharm J, 2013, 33(9): 714−718. doi: 10.13286/j.cnki.chinhosppharmacyj.2013.09.008
    [7]
    Lindsay J, Othman J, Kerridge I, et al. Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: pre-transplant predictors of survival, reactivation, and spontaneous clearance[J]. Transpl Infect Dis, 2021, 23(3): e13548. doi: 10.1111/tid.13548
    [8]
    Hakki M. Moving past ganciclovir and foscarnet: advances in CMV therapy[J]. Curr Hematol Malig Rep, 2020, 15(2): 90−102. doi: 10.1007/s11899-020-00557-6
    [9]
    Giménez E, Torres I, Albert E, et al. Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): a systematic review, meta-analysis, and meta-regression analysis[J]. Am J Transplant, 2019, 19(9): 2479−2494. doi: 10.1111/ajt.15515
    [10]
    Fan ZY, Han TT, Zuo W, et al. CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA- matched allo-HSCT[J]. Clin Exp Immunol, 2022, 208(3): 332−339. doi: 10.1093/cei/uxac047
    [11]
    Hodowanec AC, Pikis A, Komatsu TE, et al. Treatment and prevention of CMV disease in transplant recipients: current knowledge and future perspectives[J]. J Clin Pharmacol, 2019, 59(6): 784−798. doi: 10.1002/jcph.1363
    [12]
    Chemaly RF, El Haddad L, Winston DJ, et al. Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study[J]. Clin Infect Dis, 2020, 71(9): 2365−2374. doi: 10.1093/cid/ciz1210
    [13]
    von Bahr L, Blennow O, Alm J, et al. Increased incidence of chronic GvHD and CMV disease in patients with vitamin D deficiency before allogeneic stem cell transplantation[J]. Bone Marrow Transplant, 2015, 50(9): 1217−1223. doi: 10.1038/bmt.2015.123
    [14]
    Mert D, Batgi H, Merdin A, et al. BK virus-associated hemorrhagic cystitis in patients with allogeneic hematopoietic cell transplantation: report of three cases[J]. Hematol Rep, 2017, 9(2): 75−77. doi: 10.4081/hr.2017.7205
    [15]
    Tooker GM, Stafford KA, Nishioka J, et al. Intravesicular cidofovir in the treatment of BK virus–associated hemorrhagic cystitis following hematopoietic stem cell transplantation[J]. Ann Pharmacother, 2020, 54(6): 547−553. doi: 10.1177/1060028019897896
    [16]
    Cho SY, Lee DG, Kim HJ. Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy[J]. Int J Mol Sci, 2019, 20(11): 2666. doi: 10.3390/ijms20112666
    [17]
    Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation[J]. Blood, 2020, 135(19): 1619−1629. doi: 10.1182/blood.2019000956
    [18]
    Meesing A, Razonable RR. New developments in the management of cytomegalovirus infection after transplantation[J]. Drugs, 2018, 78(11): 1085−1103. doi: 10.1007/s40265-018-0943-1
    [19]
    Pierce B, Richardson CL, Lacloche L, et al. Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: a single-center study[J]. Transpl Infect Dis, 2018, 20(2): e12852. doi: 10.1111/tid.12852
    [20]
    Kim ES. Letermovir: first global approval[J]. Drugs, 2018, 78(1): 147−152. doi: 10.1007/s40265-017-0860-8
    [21]
    Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246[J]. Antimicrob Agents Chemother, 2010, 54(3): 1290−1297. doi: 10.1128/AAC.01596-09
    [22]
    Marschall M, Stamminger T, Urban A, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses[J]. Antimicrob Agents Chemother, 2012, 56(2): 1135−1137. doi: 10.1128/AAC.05908-11
    [23]
    Hostetler KY, Rybak RJ, Beadle JR, et al. In vitro and in vivo activity of 1-O-hexadecylpropanediol-3-phospho-ganciclovir and 1-O-hexadecylpropanediol- 3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infection[J]. Antivir Chem Chemother, 2001, 12(1): 61−70. doi: 10.1177/095632020101200104
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (98) PDF downloads(5) Cited by()
    Proportional views
    Related

    Copyright © Blood and Genomics苏公网安备 32028102000501号苏ICP备14047883号-6

    Address：Rooms 1318-19, Hollywood Plaza, 610 Nathan Road, Mongkok, Kowloon, HongKong

    E-mail：editorial_office@apjbg.com

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return